Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Pharmacokinetic/pharmacodynamic analyses of plasma pathophysiology biomarkers in subjects with early Alzheimer's disease following lecanemab treatment
Saved in:
| Published in: | Alzheimer's & Dementia: Translational Research & Clinical Interventions |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Pharmacokinetic/pharmacodynamic analyses of plasma pathophysiology biomarkers in subjects with early Alzheimer's disease following lecanemab treatment
- Lecanemab treatment modulates brain volume and cerebrospinal fluid pathways in early Alzheimer's disease: Insights from longitudinal magnetic resonance imaging
- A fovea‐centered retinal signature linked to plasma biomarkers in prodromal Alzheimer's disease
- Physical activity attenuates the association between allostatic load and early Alzheimer's disease‐related biomarkers in older adults
- CSF Biomarkers of Alzheimer’s Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design
- Perceptions of the use of biomarkers for Alzheimer's disease diagnosis: A systematic review and synthesis of the qualitative literature
- Metabolic and renal factors associated with plasma phosphorylated tau analytes used to detect Alzheimer's disease pathology